文献速递神经头颈PETCT

转移性脑膜瘤:神经影像学与分子影像学视角

Metastatic Meningioma: Neuroradiologic and Molecular Imaging Perspectives.
PubMed 文献 · Radiol Imaging Cancer · 2025-01-01

脑膜瘤是最常见的原发性中枢神经系统肿瘤,多数呈良性临床过程,但少数高级别脑膜瘤可表现侵袭性行为,包括局部侵犯、复发及罕见的颅外转移。转移性脑膜瘤定义为播散超出颅腔和椎管范围,报告发生率0.1%至0.76%,常见转移部位为肺、骨、肝和淋巴结。提示转移潜能的影像特征包括边缘不规则、不均匀强化、显著瘤周水肿和骨质破坏;镓68 DOTA-Tyr3-奥曲肽PET/CT和氟18氟脱氧葡萄糖PET在检测已知和隐匿转移灶中作用日益增加。分子改变如TERT启动子突变、CDKN2A/B缺失和生长抑素受体2过表达日益被认为是风险分层和靶向治疗选择的重要标志物,管理需多学科综合治疗。

要点

  • 转移性脑膜瘤定义为播散超出颅腔和椎管范围,报告发生率为0.1%至0.76%。
  • 提示转移潜能的影像特征包括边缘不规则、不均匀强化、显著瘤周水肿和骨质破坏。
  • 镓68 DOTA-Tyr3-奥曲肽PET/CT和氟18氟脱氧葡萄糖PET在检测已知和隐匿转移灶中作用增加。

核心结论

  • 转移性脑膜瘤极为罕见,报告发生率为0.1%至0.76%,常见转移部位包括肺、骨、肝和淋巴结,几乎任何器官均可受累。
  • 提示转移潜能的影像特征包括边缘不规则、不均匀强化、显著瘤周水肿和骨质破坏。
  • 分子改变包括TERT启动子突变、CDKN2A/B缺失和生长抑素受体2过表达,日益被认为是风险分层和靶向治疗选择的重要标志物。
  • 鉴于该疾病的罕见性和临床复杂性,放射科医生必须保持高度警惕,尤其是在评估高级别或复发性脑膜瘤时。

研究设计与样本

  • 综述,检索范围与纳入文献数原文未报告。

关键影像表现/征象

  • 提示转移潜能的影像特征包括边缘不规则、不均匀强化、显著瘤周水肿和骨质破坏。

诊断标准与关键数值

  • 转移性脑膜瘤定义为播散超出颅腔和椎管范围。
  • 文献报告转移性脑膜瘤发生率为0.1%至0.76%。
  • 分子标志物包括TERT启动子突变、CDKN2A/B缺失和生长抑素受体2过表达。

临床应用与阅片要点

  • 镓68 DOTA-Tyr3-奥曲肽PET/CT和氟18氟脱氧葡萄糖PET在检测和表征已知及隐匿转移灶中作用日益增加。
  • 放射科医生在评估高级别或复发性脑膜瘤时必须保持高度警惕。
  • 管理需要多学科综合治疗,包括手术、放射治疗以及新兴的系统性选择如肽受体放射性核素治疗和免疫检查点抑制剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Meningiomas are the most common primary central nervous system tumors, arising from arachnoid cap cells and typically following a benign clinical course. However, a minority of cases-particularly higher-grade meningiomas-exhibit aggressive behavior, including local invasion, recurrence, and, in rare instances, extracranial metastasis. Metastatic meningioma, defined as dissemination beyond the cranial and spinal compartments, remains exceptionally uncommon, with reported incidence ranging from 0.1% to 0.76%. Common metastatic sites include the lungs, bone, liver, and lymph nodes, although virtually any organ may be involved. Proposed mechanisms of spread include hematogenous dissemination via venous sinuses, cerebrospinal fluid seeding in high-grade variants, and possibly lymphatic dissemination. Imaging features that suggest metastatic potential include irregular margins, heterogeneous enhancement, prominent peritumoral edema, and bone destruction. Advanced modalities, such as gallium 68 DOTA-Tyr3-octreotide PET/CT and fluorine 18 fluorodeoxyglucose PET, play an increasing role in detecting and characterizing both known and occult metastatic lesions. Molecular alterations, including TERT promoter mutations, CDKN2A/B deletions, and somatostatin receptor 2 overexpression, are increasingly recognized as important markers for risk stratification and targeted therapy selection. Management requires a multimodal approach, including surgery, radiation therapy, and emerging systemic options such as peptide receptor radionuclide therapy and immune checkpoint inhibitors. Given the rarity and clinical complexity of this entity, radiologists must maintain a high index of suspicion, particularly while evaluating in high-grade or recurrent meningiomas. Keywords: Meninges, Brain/Brain Stem, Neuro-oncology, Molecular Imaging, Metastatic Meningioma, DOTATATE, High-Grade Meningioma, Somatostatin Receptor Imaging, SSTR, Peptide Receptor Radionuclide Therapy © RSNA, 2025.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Rai P, Mehta T, Kumar SS, et al. Metastatic Meningioma: Neuroradiologic and Molecular Imaging Perspectives. Radiol Imaging Cancer. 2025. PMID: 41104976. doi:10.1148/rycan.250265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。